Beyfortus approved in Japan for the prevention of RSV disease in infants
First and only RSV preventive option for broad infant population authorised for use in Japan. AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection[ ]entering their first or second RSV season.[1] Beyfortus is anticipated to be available for the upcoming 2024/25